RAS interacts with multiple targets in the cell and controls at least two signaling pathways, one regulating extracellular signal-regulated kinase (ERK) activation and the other controlling membrane ruing formation. These two pathways appear to act synergistically to cause transformation. SCH 51344 is a pyrazolo-quinoline derivative identi®ed based on its ability to derepress transformation sensitive a-actin promoter in RAStransformed cells. Previous studies have shown that SCH 51344 is a potent inhibitor of RAS-transformation. However, SCH 51344 had very little eect on the activities of proteins in the ERK pathway, suggesting that it inhibits RAS-transformation by a novel mechanism. In this study, we show that SCH 51344 speci®cally blocks membrane ruing induced by activated forms of H-RAS, K-RAS, N-RAS and RAC. Treatment of ®broblast cells with this compound had very little eect on RAS-mediated activation of ERK and JUN kinase activities. SCH 51344 was eective in inhibiting the anchorage-independent growth of Rat-2 ®broblast cells transformed by the three forms of oncogenic RAS and RAC V12. These results indicate that SCH 51344 inhibits a critical component of the membrane ruing pathway downstream from RAC and suggest that targeting this pathway may be an eective approach to inhibit transformation by RAS and other oncogenes.
Introduction
The identi®cation of mutant forms of RAS genes in a signi®cant number of human tumors has stimulated an intense eort to understand the biological function of RAS and the development of anticancer agents directed against RAS-mediated malignancies (Barbacid, 1990; Bos, 1989) . RAS proteins play an essential role in receptor-mediated signal transduction pathways that control cell proliferation and dierentiation (Egan and Weinberg, 1993; McCormick, 1994) . The three mammalian RAS genes (H, K and N) produce four proteins H-RAS, K-RAS 4A, K-RAS 4B, and N-RAS. The A and B forms of K-RAS arise from alternative splicing of a single gene (Barbacid, 1990) . RAS genes encode membrane localized guanine nucleotide binding proteins that are active in the GTP-bound state and inactive in the GDP-bound state (Egan and Weinberg, 1993; McCormick, 1994) . RAS in its GTP-bound state couples the signals of activated growth factors to downstream mitogenic eectors (Egan and Weinberg, 1993) . Increasing evidence indicates that the biological activities of RAS proteins are mediated through interaction with multiple targets in the cell which include Raf, phosphatidyl inositol (PI)-3 kinase and Ral-GDS, a guanine nucleotide dissociation factor (Davis, 1993; Feig and Schahausen, 1994) .
In tumor cells, RAS becomes oncogenically activated as a result of point mutations that interfere with the protein's intrinsic GTPase activity thereby causing RAS to become constitutively bound to GTP (Barbacid, 1990; Bos, 1989) . Activating RAS mutations are commonly found in human tumors making RAS and its downstream signaling pathways important targets for tumor therapeutics. In addition, there is substantial evidence that mutationally activated RAS plays an important role in tumorigenesis and in the maintenance of the transformed phenotype (James et al., 1993 (James et al., , 1996 Shirasawa et al., 1993) . These results argue that pharmacological agents that inhibit oncogenic RAS activity either directly or indirectly may prove useful for anti-cancer therapy in tumors in which RAS plays a contributing role.
A number of approaches have been taken to identify drugs that inhibit the transforming activity of the RAS protein either directly or indirectly. One direct approach has been to inhibit the activity of the farnesyl protein transferase (FPT) enzyme that is responsible for the transfer of a farnesyl group to the cysteine residue located in a carboxyl-terminal tetrapeptide sequence of the RAS protein (Gibbs, 1991) . A number of potent compounds that inhibit the FPTase activity have been described (Garcia et al., 1993; James et al., 1993 James et al., , 1996 Kohl et al., 1993; Bishop et al., 1995) . Several of these compounds have been shown to revert critical aspects of RAS transformation and inhibit the growth of RAS transformed cells in nude mice (Kohl et al., 1994) . In addition, a number of compounds such as azatyrosine, oxanosine and antipain that revert RAStransformed cells to a normal phenotype have been described (Cox et al., 1991; Itoh et al., 1989; ShindoOkado et al., 1989) . The mechanism by which these compounds induce a revertant phenotype is not understood.
SCH 51344 is a pyrazolo-quinoline derivative originally identi®ed based on its ability to derepress the transformation sensitive a-actin promoter in RAStransformed cells (Kumar et al., 1992 (Kumar et al., , 1995 . We have recently shown that SCH 51344 reverts several key aspects of RAS-transformation, without gross cytotoxic eects on normal cells. It also inhibits the anchorage-independent growth of a number of oncogene transformed cells such as v-abl, v-mos, vsrc, v-raf and mutant-activated MAPKK transformed cells (Kumar et al., 1995) . However, SCH 51344 treatment has very little eect on the activation of MAPKK, MAPK and p90 RSK activity in response to growth factor stimulation (Kumar et al., 1995) . Based on these ®ndings, we have proposed that SCH 51344 inhibits RAS-transformation by a novel mechanism and acts on a signaling pathway distinct from the ERK-dependent signaling pathway (Kumar et al., 1995) . In this study, we demonstrate that SCH 51344 preferentially inhibits the cell morphology pathway, induced by activated forms of RAS and RAC. Treatment of ®broblast cells with this compound had very little eect on RAS-mediated activation of the ERK and Jun kinase (JNK) cascades. We also show that SCH 51344 is eective in inhibiting the anchorageindependent growth of Rat-2 ®broblast cells transformed by the three forms of oncogenic RAS and RAC V12.
Results

Inhibition of H-RAS V12-induced membrane ruing by SCH 51344
Previous studies have shown that SCH 51344 was eective in inhibiting RAS-transformation in rat and mouse ®broblast cells and also in human tumor lines containing multiple genetic alterations in addition to activated RAS genes (Kumar et al., 1995) . However, SCH 51344 treatment of ®broblast cells had very little eect on the activation of ERK in response to growth factor stimulation or in RAS-transformed cells, suggesting that it inhibits a signaling pathway distinct from the RAS-dependent ERK signaling pathway. To investigate whether SCH 51344 treatment had any eect on RAS-induced membrane ruing, REF-52 cells were pretreated with diluent or SCH 51344 for 24 h prior to microinjection with a plasmid encoding T7-tagged H-RAS V12. Induction of membrane ruing was analysed by phase contrast microscopy. In parallel, REF-52 cells were ®xed and immunostained for the expression of H-RAS V12 protein in the cells. Microinjection of H-RAS V12 resulted in the induction of membrane rues (Bar-Sagi and Feramisco, 1986) . However, pretreatment of the cells with SCH 51344 completely inhibited RAS-induced membrane ruing (Figure 1 bottom panel) . Immuno¯uorescent staining of the injected cells con®rmed that the drug treatment had no apparent eect on the expression and the subcellular distribution of the H-RAS V12 protein (Figure 1 top  panel) . Pretreatment of the cells with 25 mM SCH 51344 for 5 h prior to microinjection was sucient to inhibit membrane ruing induced by H-RAS V12 (data not shown). In addition, the inhibitory eect was reversible, since membrane rues could be readily seen within 45 min following removal of the drug (results not shown). H-RAS V12 induced membrane ruing was inhibited in a concentration dependent manner by SCH 51344 and greater than 90% inhibition was seen at 6.25 mM (Figure 1b) .
RAC V12-induced membrane ruing is inhibited by SCH 51344
Previous studies using Swiss 3T3 ®broblasts have shown that microinjection of the RAC protein induces polymerization of actin leading to the formation of membrane rues and RAS-induced membrane ruing depends on RAC activity (Joneson et al., 1996,b; Qui et al., 1995) . To investigate whether SCH 51344 had any eect on RAC-induced membrane ruing, REF-52 cells were pretreated with the drug for 24 h prior to the microinjection of an expression plasmid encoding T7-tagged RAC V12. As shown in Figure 2 (Figure 2b ), similar to H-RAS V12 and the concentration required for half maximal inhibition was less than 6.25 mM. These results indicate that the drug interferes with the ability of RAS to induce membrane ruing at a point downstream from RAC.
SCH 51344 inhibits membrane ruing induced by activated forms of H-, K-and N-RAS Next, we wished to examine if SCH 51344 was eective in blocking membrane ruing induced by the three forms of oncogenic RAS (H-, K-and N-RAS) proteins. REF-52 cells pretreated with diluent or SCH 51344 (12.5 mM) were microinjected with expression plasmids containing T7-tagged H-RAS V12, K-RAS V12 and N-RAS D12 coding sequences, individually and the ability of SCH 51344 to inhibit membrane ruing was assessed as described above. The results shown in Figure 3 , demonstrate that SCH 51344 was equally eective in inhibiting membrane ruing induced by all three forms of RAS and RAC V12. Again, pretreatment of the cells with the drug for 5 h was sucient to inhibit membrane ruing and the inhibitory eect was reversible, since removal of the drug led to the reappearance of the rues within 45 min (results not shown).
Stimulation of ERK-2 activity by activated forms of H-, K-and N-RAS is not inhibited by SCH 51344
Next, we wished to determine whether the drug had any eect on the activation of ERK in response to the expression of the three forms of oncogenic RAS proteins. COS-1 cells were cotransfected with a plasmid encoding haemagglutinin-antigen (HA) epitope tagged ERK-2 along with either H-RAS V12, K-RAS V12 or N-RAS D12 expression vectors. Following treatment with SCH 51344 for 24 h, ERK-2 was isolated by immunoprecipitation and its activity was measured in an immune complex kinase assay with myelin basic protein (MBP) as the substrate. As shown in Figure 4 , expression of the activated forms of H-, Kand N-RAS resulted in the stimulation of ERK-2 activity and treatment with SCH 51344 did not block this stimulation. The drug treatment had very little eect on the expression levels of transiently expressed RAS proteins and the epitope tagged ERK-2 under these conditions (Figure 4 ). This result is not restricted to COS cells; this experiment was also repeated in Rat-2 and NIH3T3 ®broblast cells with identical results (data not shown). These results con®rm and extend our previous observations that the drug treatment had very little eect on the activation of ERK signaling cascade in response to either growth factor stimulation or oncogenic RAS expression (Kumar et al., 1995) .
RAS V12 and RAC V12-induced stimulation of JNK activity is not inhibited by SCH 51344
Next, we wanted to see if the drug had any eect on RAS V12-and RAC V12-mediated activation of JNK activity. COS-1 cells were cotransfected with a plasmid encoding FLAG-tagged JNK1 along with either H-RAS V12, K-RAS V12, N-RAS D12 or RAC V12 expression plasmids separately followed by treatment with SCH 51344 for 24 h. JNK activity was assayed with glutathione-S-transferase (GST) fused to c-Jun as the substrate (Joneson et al., 1996a ). Activation of JNK by H-RAS V12, K-RAS V12 and N-RAS D12 or RAC V12 was not altered by SCH 51344 treatment ( Figure 5 ). The expression levels of RAS, RAC and JNK proteins, as determined by immunoblot analysis, were found to be similar in each sample ( Figure 5 ).
This experiment was also repeated in Rat-2 cells with identical results (data not shown). These results clearly indicate that SCH 51344 treatment had very little eect on the two MAPK cascades initiated by RAS and its eect is limited to the inhibition of membrane ruing pathway downstream of RAC.
Inhibition of anchorage-independent growth of H-RAS V12, K-RAS V12, N-RAS D12 and RAC V12 transformed ®broblast cells by SCH 51344
The results described above suggested that SCH 51344 should be eective in blocking transformation by oncogenic forms of all three RAS proteins and RAC. To determine this, the ability of SCH 51344 to block the anchorage-independent growth of Rat-2 ®broblast cells transformed by H-RAS V12, K-RAS V12, N-RAS D12 and RAC V12 transformed Rat-1 cells, was examined in a soft-agar colony formation assay. The results, shown in Figure 6 indicate that SCH 51344 is eective in blocking the anchorage-independent growth of Rat-2 cells transformed by H-, K-and N-RAS. As expected, the compound also inhibits the ability of RAC V12 transformed Rat-1 cells to grow in soft-agar. A schematic illustration of the signaling pathways activated by RAS and the proposed site of action of SCH 51344 is shown in Figure 7 .
Discussion
In this study, we have analysed the eects of SCH 51344 on dierent signaling cascades activated by RAS. Our ®ndings demonstrate that SCH 51344 speci®cally inhibits the RAS-mediated cell morphology pathway at a point downstream from RAC. The rapid reversibility of the inhibitory eects of the drug rule out the possibility that these eects re¯ect a general toxic eect of the drug. Recent studies have demonstrated that RAS activates at least two distinct eector pathways, the cell-morphology pathway and MAP kinase pathway (Joneson et al., 1996b) . The MAPK pathway involves a series of cytoplasmic serine, threonine kinases (Davis, 1993) and the cell morphology pathway is mediated by members of the RHO family of GTP binding proteins which regulate organization of the actin cytoskeleton (Downward, 1992; Hall, 1994) . RHO controls stress ®ber formation, whereas RAC regulates the formation of lamellipodia and membrane rues (Hall, 1994; Ridley et al., 1992) .
Several lines of evidence indicate that stimulation of the cell morphology pathway is critical for the transforming activity of RAS. Dominant-negative ASN-17 mutant of RAC inhibits focus formation by oncogenic RAS (Qui et al., 1995) . In addition, RAC V12 synergizes strongly with Raf-CAAX, a Raf kinase targeted to the plasma membrane by virtue of the addition of a carboxy-terminal localization signal from K-RAS, in focus formation assay (Qui et al., 1995) . An eector binding loop mutant of activated H-RAS, H-RAS V12S35 which is defective in the stimulation of membrane ruing was found to be severely impaired in its ability to induce foci in ®broblast cells. However, this mutant still interacted with Raf-1, retained the ability to activate ERK-2 and induced SRE-dependent gene transcription (White et al., 1995) . Thus, SCH 51344 represents a pharmacological agent that interferes with the transforming activity of RAS by speci®cally targeting the cell morphology pathway. Consistent with this idea are our previous ®ndings that SCH 51344 reverts several critical aspects of RAStransformation, such as restoration of actin ®lament organization and morphological changes and inhibition of anchorage-dependent and -independent growth (Kumar et al., 1995) .
RAS also activates two protein kinases, Raf-1 and MEK kinase (MEKK) (Minden et al., 1994 . Raf-1 contributes directly to ERK activation but not to JUN kinase (JNK) activation, whereas MEKK participates in JNK activation but caused ERK activation only when overexpressed (Minden et al., 1994) . Hence, RAS activation triggers two divergent signaling cascades that activate distinct MAPKs with dierent substrate speci®cities and transcriptional functions. While the role of ERK activation in RAS-mediated transformation is clearly established (Cowley et al., 1994) , the activation of the JNK pathway appears not to be essential for RAS and RAC-transformation (Joneson et al., 1996a; Lamarche et al., 1996) . Our results clearly show that SCH 51344 has very little eect, if any on RAS-mediated activation of the ERK and JNK signaling cascades. Therefore, inhibition of the cell morphology pathway might be sucient to block the transforming function of RAS.
The ability of SCH 51344 to inhibit the anchorageindepednent growth of RAC V12 transformed Rat-1 cells is in agreement with the fact that the point of inhibition of the cell morphology pathway by SCH 51344 is downstream from RAC. One of the interesting features of SCH 51344 is its ecacy in inhibiting transformation by oncogenic versions of all three forms of RAS. Recent studies have shown that the prenylation and membrane localization of H-RAS is sensitive to FPT inhibitors (James et al., 1996) . However, N-, Ka-and Kb-RAS proteins incorporated geranyl geranyl isoprene group in the presence of FPT inhibitors and remain associated with the membrane fraction (Whyte et al., 1997; James et al., 1996) . The transformed morphology of Rat-1 cells transformed by K-Ras V12 was found to be resistant to the action of FPT inhibitors (James et al., 1996) . In contrast, we observe that SCH 51344 inhibits ruing and soft-agar growth of all RAS forms.
The pathway by which RAS and RAC stimulate membrane ruing pathway is not clearly established. Recently, a number of RAC1-interacting proteins, have been isolated using the yeast two-hybrid system (Burbelo et al., 1995; Ishizaki et al., 1996; Van Aelst et al., 1996) . POR1 binds directly to RAC1 in a GTPdependent fashion and truncated versions of POR1 inhibit the induction of membrane ruing by an activated mutant of RAC1, suggesting a potential role for POR1 in RAC-mediated cell morphology pathway (Van Aelst et al., 1996) . The ser/thr kinase, p160 ROCK which was originally identi®ed as a putative RHO target (Ishizaki et al., 1996) , has been recently shown to interact also with activated RAC L61 (Lamarche et al., 1996; Van Aelst et al., 1996) . Studies with mutants of RAC defective for membrane ruing, suggest that this kinase might play a role in RAC-induced cytoskeletal changes (Lamarche et al., 1996) . Identi®cation of the speci®c target protein that is inhibited by SCH 51344 may provide a novel, therapeutically useful target.
Materials and methods
Plasmids
Human cDNAs encoding H-RAS V12, K-RAS 4BV12 and N-RAS D12 were subcloned into the mammalian expression vector pCGT. The mammalian expression vector pCGT was given as a gift from Winship Herr (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). pCGT contains a cytomegalovirus promoter and multiple cloning sites allowing the cloning of genes downstream of the N-terminal T7 epitope. The cDNAs were ampli®ed by polymerase chain reaction using Pfu DNA polymerase. The primers used are as follows: H-RAS V12 (5'-CAATCTA-GAATGACGGAATATAAG-3') and (5'-CAAGGATCCT-CAGGAGAGCACACA-3'), K-RAS 4BV12 (5'-CCCAC-TAGTATGACTGAATATAAA-3') and (5'-GATGGATC-CTTACATAATTACACA-3'), and N-RAS D12 (5'-CAAT-CTAGAATGACTGAGTACAAA-3') and (5'-CAAGGA-TCCTTACATCACCACACA-3'). The primers for the respective constructs created a 5'XbaI site (H-RAS V12, N-RAS D12), a 5'SpeI site (K-RAS 4BV12) and a 3'BamHI site (H-RASV12, K-RAS 4BV12, N-RAS D12) allowing the PCR product to be subcloned into the XbaI/BamHI sites of pCGT. RAC V12/pCGT was provided by Linda Van Aelst (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). The FLAG-tagged JNK construct was provided by Rick Cerione (Cornell University, Ithaca, NY). The expression plasmid encoding hemagglutinin (HA) epitope-tagged ERK2 has been previously described (Joneson et al., 1996b) .
Antibodies
The antibodies used for immunoprecipitation, immunoblotting and immuno¯uorescence were obtained as follows: anti-T7 mouse monoclonal antibody (Novagen), anti-HA mouse monoclonal antibody 12CA5 (Babco), anti-FLAG M2 antibody (Kodak Scienti®c Imaging Systems), anti-JNK rabbit polyclonal antibody (Santa Cruz Biotechnology), horseradish peroxidase antibodies (Cappel) and rhodamine-conjugated goat anti-mouse (Cappel).
Cell culture
REF-52 cells were cultured in Dulbecco's Modi®ed Eagles' Medium (DMEM) supplemented with 10% fetal calf serum in a humidi®ed incubator with 6.3% CO 2 at 378C. For microinjection experiments, REF-52 cells were plated on grided glass coverslips and grown to con¯uency prior to serum starvation. COS-1 cells, Rat-2 cells and its transformed derivatives were grown in DMEM supplemented with 5% fetal calf serum in a humidi®ed incubator with 5% CO 2 at 378C. Rat-2 cells transformed by H-RAS V12, K-RAS V12 and N-RAS D12 were a kind gift from Dr Paul Kirschmeier (Schering-Plough Research Institute). RAC V12 transformed Rat-1 cells were a kind gift from Dr Marc Symons (Onyx Pharmaceuticals, Richmond, CA).
Transient transfections
Transient transfections using a calcium phosphate method were performed as previously described (Kumar et al., 1992) . Brie¯y, DNA was diluted in a TRIS/EDTA buer (pH 7) containing 2 M CaCl 2 which was then added to N-(2-hydroxyethyl) piperazine -N' -(2' -ethanesulfonic acid) (HEPES) Na 2 HPO 4 buer. The solution was incubated at room temperature for 30 min before addition to the cells. After 16 h the media was aspirated, washed brie¯y with DMEM and replaced with DMEM supplemented with 5% fetal calf serum. The cells were serum starved and treated with SCH 51344 or vehicle (dimethyl sulfoxide) for 24 h prior to harvesting.
Immunoprecipitation and immune complex kinase assays
For immunoprecipitation experiments, COS-1 cells were washed twice with cold PBS and lysed in (10 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 0.6% Triton X-100, 50 mM NaF, 1 mM sodium vanadate, 10 mg leupeptin per ml, 1% aprotinin, 10 mg peptstatin per ml, 1 mM phenyl methyl sulfonyl¯uoride, 10 mg soybean trypsin inhibitor per ml, 1 mM okadaic acid, 10 mM benzamidine) for the cJun kinase assay and in (10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 50 mM NaF, 1 mM sodium vanadate, 10 mg leupeptin per ml, 1% aprotinin, 10 mg pepstatin per ml, 1 mM phenyl methyl sulfonyl¯uoride, 10 mg soybean trypsin inhibitor per ml, 1 mM okadaic acid, 10 mM benzamidine) for the ERK2 immune complex assay. The lysates were clari®ed by centrifugation at 48C for 20 min at 14 000 g. For the c-Jun kinase assay, the lysates were pre-incubated with protein G-sepharose beads for 30 min at 48C. The lysates were incubated with anti-FLAG antibody (c-Jun kinase assay) or anti-HA mouse monoclonal antibody 12CA5 (ERK-2 kinase assay) for 2 h at 48C and subsequently incubated with protein G-sepharose beads or protein A-sepharose beads for 1 h, respectively. Immune complexes were pelleted by centrifugation at 48C for 15 s at 1000 g. The beads were washed twice with cold lysis buer and twice with cold kinase reaction buer (20 mM HEPES (pH 7.6), 20 mM MgCl 2 , 20 mM b-glycerol phosphate, 0.1 mM sodium vanadate, 2 mM DTT, 20 mM ATP) for the c-Jun kinase assay and in (25 mM Tris pH 7.4, 0.5 mM sodium vanadate, 20 mM MgCl 2 , 2 mM MnCl, 20 mM ATP) for the ERK-2 kinase assay.
The c-Jun kinase assay was performed by incubating the immune-complexes with 3 mg glutathione S-transferase (GST) fused to the N-terminal c-Jun per reaction and 10 mCi [g-32 P]ATP (DuPont-NEN; 6000 Ci/mmol) in kinase reaction buer. The ERK-2 reaction was initiated by the addition of 10 mCi [g-32 P]ATP (DuPont-NEN; 6000 Ci/mmol) and 0.2 mg/ml myelin basic protein (Sigma) in kinase reaction buer. The reactions were incubated for 30 min at 308C and were terminated by the addition of sodium dodecyl sulfate (SDS) sample buer. The products were resolved using SDSpolyacrylamide gel electrophoresis and visualized by autoradiography.
Immunoblot analyses
For immunoblotting, the samples were resolved using SDSpolyacrylamide electrophoresis and transferred to nitrocellulose membranes (Schleicher & Schuell) . The membranes were incubated with either anti-T7 mouse monoclonal antibody (1 : 10 000, anti-HA mouse monoclonal antibody 12CA5 (1 : 10 000) or anti-JNK rabbit polyclonal (1 : 1000) and immunoreactive bands were observed with goat antimouse or rabbit secondary antibodies coupled to horseradish peroxidase (1 : 20 000) using enhanced chemiluminescence reagents (Dupont-NEN).
Microinjection and Immuno¯uorescence
REF-52 cells were grown to con¯uency on grided glass coverslips, serum starved for 24 h and treated with varying concentrations of SCH 51344 or vehicle (DMSO) for 24 h prior to microinjection. 50 ng/ml of H-RAS V12, K-RAS 4BV12, N-RAS D12 or RACV12 each resuspended in DNA microinjection buer (50 mM HEPES (pH 7.2), 100 mM KCl and 5 mM NaH 2 PO 4 ) were injected into the nuclei of all the cells of a speci®c square on the coverslip. Ruing activity was scored by the appearance of transient phase-dense bands actively traversing across the upper surface of the cells. The rues were observed and counted 4 h after injection using phase contrast microscopy. To clarify the phase contrast images of the rues, the auto-trace function of Corel Draw computer software was used. This function recognizes areas of increased phase density and intensi®es the regions containing equal pixel number. The percentage of cells ruing was quantitated by using the following formula: % cells ruing = # cell ruing/# cells expressing the injected protein. The later parameter was determined by immuno¯uorescence staining as described.
For immuno¯uorescence, the RAS and RAC injected cells were ®xed with 3.7% formaldehyde in phosphate-buered saline (PBS) for 1 h at 4 and 12 h after injection, respectively. The injected cells were permeabilized with 0.1% Triton X-100 for 3 min at room temperature and washed 36 for 5 min each with PBS. Anti-T7 antibody was diluted 1 : 300 in 1% BSA/PBS and incubated with the cells for 1 h in a 378C humidi®ed chamber. Rhodamine conjugated goat anti-mouse, diluted 1 : 100 in 1% BSA/PBS, was added and incubated as described for the primary antibody. The cells were photographed using a Zeiss Axiovert microscope.
Soft-agar assays
Soft-agar assays were carried out as described previously (Kumar et al., 1995) . Brie¯y, transformed Rat-2 and RAC V12 transformed Rat-1 cells were seeded at a density of 1610 4 cells/100 mm plate in a 0.3% agarose layer in DMEM with 10% FBS over a bottom 0.6% agarose layer in DMEM without serum. The drug was included in the top layer of agar and the incubations were carried out for 2 weeks. The colonies were stained with a 0.2% solution of 3-(4,5-dimethylthiazole-2-yl)-2,5 diphenyltetrazolium bromide and photographed.
